Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes

Table 3

Odds ratio of hypoglycaemia and lipid profiles for cardiovascular disease.

	OR (95% CI)	value
Hypoglycaemia for CVD
Model one		<0.0001
Nonhyperglycemia	Reference
Mild hyperglycemia	2.37 (1.72–3.26)
Severe hyperglycemia	5.80 (3.60–9.35)
Model two		<0.0001
Nonhyperglycemia	Reference
Mild hyperglycemia	2.64 (1.85–3.76)
Severe hyperglycemia	6.59 (3.79–11.45)
Model three
Nonhyperglycemia	Reference	<0.0001
Mild hyperglycemia	2.64 (1.85–3.76)
Severe hyperglycemia	6.59 (3.79–11.45)
Lipid profile for CVD
Model four
LDL cholesterol, mmol/L	1.11 (1.01–1.24)	0.0351
HDL cholesterol, mmol/L	0.69 (0.63–0.77)	<0.0001
Triglyceride, mmol/L	1.12 (1.06–1.78)	<0.0001
Model five
LDL cholesterol, mmol/L	0.95 (0.84–1.07)	0.3703
HDL cholesterol, mmol/L	0.89 (0.80–0.99)	0.0299
Triglyceride, mmol/L	1.08 (1.02–1.14)	0.0160
Model six
LDL cholesterol, mmol/L	0.93 (0.82–1.05)	0.2462
HDL cholesterol, mmol/L	0.87 (0.78–0.97)	0.0097
Triglyceride, mmol/L	1.08 (1.01–1.14)	0.0166

Model one: not adjusted for other variables.
Model two: adjusted for age, sex, BMI, systolic blood pressure and log-transformed urinary albumin to creatinine ratio, and drug use (statins, other lipid lowering drugs, renin-angiotensin system inhibitors, oral antidiabetes drugs [OADs] only, glucagon-like peptide-1 based treatment, basal insulin based treatment, and premixed insulin based treatment).
Model three: further adjusted for LDL-C, HDL-C, and triglyceride.
Model four: not adjusted for other variables.
Model five: adjusted for age, sex, BMI, systolic blood pressure, LDL-C, HDL-C, triglyceride and log-transformed urinary albumin to creatinine ratio, and drug use (statins, other lipid lowering drugs, renin-angiotensin system inhibitors, and oral antidiabetes drugs [OADs] only).
Model six: adjusted for the variables listed in model five and hypoglycaemia.